Alliance Pharma : (6.7MB)

This presentation ("Presentation") contains information which is not audited. This Presentation is for personal use only and is provided for information purposes and is not intended for distribution to any person or entity, or for use by any person or entity, in any jurisdiction in any country where such distribution or use would be contrary to any laws or regulations, or which would subject Alliance Pharma Plc or any member of the Alliance Group to any legal or regulatory registration requirement.

No representation or warranty, express or implied, is or will be made in relation to the accuracy, fairness or completeness of the information or opinions made in this Presentation.

All statements in this Presentation reflect the knowledge and information available to the Alliance Group at the time of its preparation. Certain statements included or incorporated by reference within this Presentation may constitute "forward-looking statements" in respect of the Group's performance, operations, financial condition and/or prospects. By their nature, "forward-looking statements" will involve a number of risks, uncertainties and assumptions and therefore actual results or events may differ materially from those which are either expressed or implied by those "forward looking statements". Accordingly, no guarantees or assurance can be given that any particular expectation will be met, and reliance cannot and should not be placed on any "forward-looking statement".

Furthermore, all "forward-looking statements" regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. No responsibility is accepted, and the Alliance Group does not undertake any obligation, to update or amend any "forward-looking statement" resulting from any new information, future events or otherwise. Nothing in this Presentation should be construed as a profit forecast.

This Presentation does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in Alliance Pharma Plc, nor shall it or any

part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decision relating thereto, nor does it constitute

a recommendation regarding the shares of Alliance Pharma Plc or any invitation or inducement to engage in investment activity under Section 21 of the Financial Services and Markets Act 2000 (as amended).

Past performance cannot be relied upon as an indication of future performance. Any liability arising from anything in this Presentation shall be governed and construed in accordance with English Law, and neither Alliance Pharma Plc nor any member of the Alliance Group or its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss arising out of or in connection with this Presentation or its use or

its contents.

Nothing in this Presentation shall exclude any liability under applicable laws or regulations that cannot be excluded in accordance with such laws or regulations.

Revenue growth boosted by US acquisitions and FX

 +1% growth in Group see-through revenues to £172.0m

 Like for like* see through revenues down 6%

 Consumer revenues -3% CER** to £125.2m

 Kelo-Cote impacted by COVID-related lockdowns in China, -6% CER to £50.0m

 Amberen affected by declines in bricks and mortar market and loss of key discount store account, -30% to £14.9m

• • Other Consumer Healthcare brands solid, +14% CER to £38.4m
• Prescription Medicines stable, -2% CER to £46.8m